Industry
Biotechnology
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Loading...
Open
0.70
Mkt cap
1.6M
Volume
644K
High
0.70
P/E Ratio
-0.05
52-wk high
13.20
Low
0.53
Div yield
N/A
52-wk low
0.53
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 7:17 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 4:32 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 1:14 pm
Portfolio Pulse from Benzinga Insights
October 15, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 7:49 pm
Portfolio Pulse from Avi Kapoor
September 12, 2024 | 6:01 pm
Portfolio Pulse from Avi Kapoor
September 12, 2024 | 4:10 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 3:16 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 2:55 pm
Portfolio Pulse from Avi Kapoor
September 12, 2024 | 2:23 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.